Cargando…
Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic forms of...
Autores principales: | Korecka, Joanna A., Thomas, Ria, Hinrich, Anthony J., Moskites, Alyssa M., Macbain, Zach K., Hallett, Penelope J., Isacson, Ole, Hastings, Michelle L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393423/ https://www.ncbi.nlm.nih.gov/pubmed/32736291 http://dx.doi.org/10.1016/j.omtn.2020.06.027 |
Ejemplares similares
-
Neurite Collapse and Altered ER Ca(2+) Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation
por: Korecka, Joanna A., et al.
Publicado: (2018) -
Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013) -
Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)